A biopharmaceutical company with three proprietary products on the market and a R&D of drug & diagnostic products in development for the treatment of enlarged prostate, Alzheimer's disease contamination of food and drink products and bacterial infections.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
There are far too many of these types of pharmaceutical companies out there...plenty of promise, huge valuation and failure to deliver. Nymox currently has one...yes..only one drug currently in late stage trials to treat enlarging prostates. The company has managed just 450k in sales for the entire year yet is valued at over 183 million dollars. Losses are increasing, and based on my estimates, they dont even have enough cash to get out of Q1 2008! Over 400 times price to sales, 58 times book, and increasing losses..where's the buy button?!! If you look historically at the long-term chart, this falls mercilessly for 2-3 months after every large rise.
Nero
Sagetrade